Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients.

The company’s PATHWAY HER2 antibody test—used to help screen patients for treatment with Enhertu (trastuzumab deruxtecan-nxki), the antibody-drug conjugate jointly developed by Daiichi Sankyo ...

Approval of Enhertu was granted to AstraZeneca and Daiichi Sankyo. More Information ...

who may be eligible for treatment with Enhertu (trastuzumab deruxtecan; AstraZeneca and Daiichi Sankyo). 1 Last week, the FDA approved Enhertu as the first HER2-directed therapy for adults with ...

MONDAY, Feb. 3, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone ...

Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three of the largest licensing ...